Initiate Phase 1-enabling preclinical studies for ESCAPE
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Jan 2024
- Due
- 31 Dec 2024
- Delivered
- December 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate Phase 1-enabling preclinical studies in 2024”
What we found
Evidence strength A What the grades mean
Beam Therapeutics initiated Phase 1-enabling preclinical toxicology studies for its ESCAPE platform in December 2024, meeting the commitment to initiate these studies within the 2024 calendar year.
-
A Beam Therapeutics Inc. 8-K filed 2025-01-13
“ESCAPE programs named (BEAM-103, BEAM-104) with Phase 1-enabling tox studies initiated in December 2024” ✓ confirmed on the page
-
A Beam Therapeutics Inc. 8-K filed 2025-02-25
“The company initiated Phase 1-enabling preclinical toxicology studies for ESCAPE in December.” ✓ confirmed on the page
Market reaction: the shares moved -13.5% against the S&P 500 over the three sessions around the disclosure (10 Jan 2025 to 15 Jan 2025). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 3 versions
-
Version 1 · original · stated 8 Jan 2024
Deadline 31 Dec 2024 (“in 2024”)
-
Version 2 · stated 27 Feb 2024
Deadline 31 Dec 2024 (“2024”) · wording expected
“anticipates initiating Phase 1-enabling preclinical studies for the program in 2024”
-
Version 3 · stated 9 Dec 2024
Deadline 31 Dec 2024 (“by End of 2024”) · wording firm
“Beam on Track to Initiate Phase 1-enabling Studies by End of 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- ESCAPE preclinical studies
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-BEAM-003260 · Corrections policy